5 results
management alendronate anorexia bulimia clinical eatingdisorders ebm icucard insulin insulinmediatedlipohypertrophy lipohypertrophy nervosa romosozumab
Eating disorders: Initial assessment in primary care #Management #PrimaryCare #Endo #EatingDisorders #Anorexia #Bulimia #Nervosa #BMJ
disorders: Initial assessment ... care #Management #PrimaryCare ... #Endo #EatingDisorders ... Bulimia #Nervosa #BMJ
Management of type 2 diabetes in adults: summary of updated NICE guidance #Management #IM #PrimaryCare #Endo
guidance #Management #IM ... #PrimaryCare #Endo ... #DM2 #BMJ
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis - Incidence of New Vertebral, Clinical,
Fracture #EBM #PrimaryCare ... #Endo #IM #Romosozumab ... #Alendronate #NEJM
Insulin-Mediated Lipohypertrophy - Two painless, rubbery, hyperpigmented masses were noted near the umbilical area. The patient
#Clinical #Derm ... #Endo #PrimaryCare ... Lipohypertrophy #Insulin #NEJM
#ICUCard RENAL GFR 90-131 mL/min ((140-age)*Wt)/(72*Cr) Glomerular Filtration Rate (Cockcroft) CI Cr 90-131 mL/min (CrU * volume)/CrS Creatinine Clearance FENa 0.0-1.0 % ((U/P Na)/(U/P Cr))*100 Fractional Excretion of Na+ Na req mEq (125-Na)*0.6*Wt Required Sodium FE Urea
Ideal Body Weight BMI ... 18.5-25 kg*m2 ... Individual Patient assessment ... Bumetanide: IV or IM ... x4 q15-30min) *IM
No results found for "Assessment primarycare nejm bmj endo derm im dm2"
Try removing search terms or sorting by relevance
Or Upload an image for you and others searching for #Assessment #primarycare #nejm #bmj #endo #derm #im #dm2